| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y;Tan C.-T;Chen C.-W;Da-Liang Ou;Cheng A.-L;Hsu C.; Lin Y.-Y; Tan C.-T; Chen C.-W; DA-LIANG OU; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2020-06-17T03:01:53Z |
Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells
|
Ou D.-L.;Shen Y.-C.;Sung-Liang Yu;Chen K.-F.;Yeh P.-Y.;Fan H.-H.;Feng W.-C.;Wang C.-T.;Lin L.-I.;Hsu C.;Cheng A.-L.; Ou D.-L.; Shen Y.-C.; SUNG-LIANG YU; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; Lin L.-I.; Hsu C.; Cheng A.-L. |
| 國家衛生研究院 |
2020-05-28 |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang, NJ;Chen, MH;Yang, SH;Hsu, C;Yen, CJ;Tsou, HH;Su, YY;Chen, JS;Shan, YS;Chen, LT |
| 臺大學術典藏 |
2020-05-26T09:27:34Z |
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer
|
Hsu C;Yeh K.-H;Hong R.-L;Chih-Hsin Yang;Lin M.-T;Chen Y.-C;Cheng A.-L.; Hsu C; Yeh K.-H; Hong R.-L; CHIH-HSIN YANG; Lin M.-T; Chen Y.-C; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H;Cheng A.-L;Hsu C;Chih-Hsin Yang;Lu Y.-S;Lin C.-C;Bu C.-F;Yeh K.-H.; Hsu C.-H; Cheng A.-L; Hsu C; CHIH-HSIN YANG; Lu Y.-S; Lin C.-C; Bu C.-F; Yeh K.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Perng R.-P.; Chih-Hsin Yang;Tsai C.M;Wang L.S;Lee Y.C;Chang C.J;Lui L.T;Yen S.H;Hsu C;Cheng A.L;Liu M.Y;Chiang S.C;Chen Y.M;Luh K.T;Huang M.H;Yang P.-C;Perng R.-P.; CHIH-HSIN YANG; Tsai C.M; Wang L.S; Lee Y.C; Chang C.J; Lui L.T; Yen S.H; Hsu C; Cheng A.L; Liu M.Y; Chiang S.C; Chen Y.M; Luh K.T; Huang M.H; Yang P.-C |
| 臺大學術典藏 |
2020-05-26T09:27:30Z |
Quality of life of lung cancer patients: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and QLQ-LC13
|
Chie W.-C;Chih-Hsin Yang;Hsu C;Yang P.-C.; Chie W.-C; CHIH-HSIN YANG; Hsu C; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trials
|
Kuo S.-H;Chih-Hsin Yang;Yu C.-J;Hsu C;Cheng A.-L;Yang P.-C.; Kuo S.-H; CHIH-HSIN YANG; Yu C.-J; Hsu C; Cheng A.-L; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Hsu C;Shen Y.-C;Chih-Hsin Yang;Yeh K.-H;Lu Y.-S;Hsu C.-H;Liu H.-T;Li C.-C;Chen J.-S;Wu C.-Y;Cheng A.-L.; Hsu C; Shen Y.-C; CHIH-HSIN YANG; Yeh K.-H; Lu Y.-S; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-26T09:27:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Lu Y.-S;Hsu C;Li C.-C;Kuo S.-H;Yeh K.-H;Chih-Hsin Yang;Hsu C.-H;Wu C.-Y;Cheng A.-L.; Lu Y.-S; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; CHIH-HSIN YANG; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
